Funding for Risky Biotechs Is Returning
PositiveTechnology
- Publicly traded drug developers raised over $13 billion through share sales in the fourth quarter, marking the highest amount in more than four years. This resurgence indicates a renewed investor interest in the biotech sector, particularly in companies perceived as high-risk.
- The significant influx of capital into risky biotechs suggests a potential shift in market sentiment, which could lead to increased innovation and development within the pharmaceutical industry, ultimately benefiting patients and healthcare advancements.
— via World Pulse Now AI Editorial System